Ai‐Hong Ma

1.2k total citations
19 papers, 766 citations indexed

About

Ai‐Hong Ma is a scholar working on Molecular Biology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Ai‐Hong Ma has authored 19 papers receiving a total of 766 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Surgery and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Ai‐Hong Ma's work include Bladder and Urothelial Cancer Treatments (7 papers), Photodynamic Therapy Research Studies (4 papers) and Nanoplatforms for cancer theranostics (4 papers). Ai‐Hong Ma is often cited by papers focused on Bladder and Urothelial Cancer Treatments (7 papers), Photodynamic Therapy Research Studies (4 papers) and Nanoplatforms for cancer theranostics (4 papers). Ai‐Hong Ma collaborates with scholars based in United States, China and Taiwan. Ai‐Hong Ma's co-authors include Ralph W. deVere White, Clifford G. Tepper, Xu‐Bao Shi, Hsing‐Jien Kung, Chong-xian Pan, Lingru Xue, Susan Airhart, James Keck, Wei Shi and Michael A. Brehm and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Ai‐Hong Ma

18 papers receiving 757 citations

Peers

Ai‐Hong Ma

ONCOL

IMMUN

PRM

Jingshu Meng China

Lanlan Hui China

Kaoru Yamawaki Japan

Jiong Li United States

Bizhan Bandarchi Canada

Alice Agliano Spain

Yuan‐Tong Liu China

Amber E. de Groot United States

Camilla L. Christensen Denmark

Elisa Melucci Italy

Jingshu Meng China

Ai‐Hong Ma

444 ×1.1

238 ×1.0

ONCOL

215 ×0.9

244 ×1.6

IMMUN

186 ×1.3

PRM

Citations per year, relative to Ai‐Hong Ma Ai‐Hong Ma (= 1×) peers Jingshu Meng

Countries citing papers authored by Ai‐Hong Ma

Since Specialization

Citations

This map shows the geographic impact of Ai‐Hong Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ai‐Hong Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ai‐Hong Ma more than expected).

Fields of papers citing papers by Ai‐Hong Ma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ai‐Hong Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ai‐Hong Ma. The network helps show where Ai‐Hong Ma may publish in the future.

Co-authorship network of co-authors of Ai‐Hong Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Ai‐Hong Ma. A scholar is included among the top collaborators of Ai‐Hong Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ai‐Hong Ma. Ai‐Hong Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Pan, Chong-xian, Juan Garisto, Lori B. Lerner, et al.. (2025). A phase I first-in-human clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in therapy-resistant non-muscle-invasive bladder cancer (NMIBC).. Journal of Clinical Oncology. 43(5_suppl). 806–806. 1 indexed citations

Siddiqui, Salma, Christopher A. Lucchesi, Benjamin A. Mooso, et al.. (2023). Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer. Scientific Reports. 13(1). 9617–9617. 7 indexed citations

Zhu, Zheng, Ai‐Hong Ma, Hongyong Zhang, et al.. (2022). Phototherapy with Cancer-Specific Nanoporphyrin Potentiates Immunotherapy in Bladder Cancer. Clinical Cancer Research. 28(21). 4820–4831. 19 indexed citations

Rehman, Hasibur, Darshan S. Chandrashekar, Saroj Nepal, et al.. (2022). ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. JCI Insight. 7(16). 40 indexed citations

Yu, Weimin, Xiangdong Xue, Ai‐Hong Ma, et al.. (2020). Self‐Assembled Nanoparticle‐Mediated Chemophototherapy Reverses the Drug Resistance of Bladder Cancers through Dual AKT/ERK Inhibition. Advanced Therapeutics. 3(8). 14 indexed citations

Lin, Tzu‐yin, Yanjun Zhu, Yuanpei Li, et al.. (2019). Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia. Nanomedicine Nanotechnology Biology and Medicine. 20. 102004–102004. 18 indexed citations

Henderson, Paul T., et al.. (2019). PDX validation of a 3D microtumor platform.. Journal of Clinical Oncology. 37(15_suppl). 3029–3029. 1 indexed citations

Long, Qilai, Tzu‐yin Lin, Yee Huang, et al.. (2018). Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model. Nanomedicine Nanotechnology Biology and Medicine. 14(3). 789–799. 28 indexed citations

Pan, Chong-xian, Wei Shi, Ai‐Hong Ma, et al.. (2017). Humanized mice (humice) carrying patient-derived xenograft (PDX) as a platform to develop immunotherapy in bladder cancer (BCa).. Journal of Clinical Oncology. 35(6_suppl). 381–381. 4 indexed citations

10.

Yao, Li‐Chin, Mingshan Cheng, Danying Cai, et al.. (2017). Humanized mice in studying efficacy and mechanisms of PD‐1‐targeted cancer immunotherapy. The FASEB Journal. 32(3). 1537–1549. 234 indexed citations

11.

Lin, Tzu‐yin, Wenchang Guo, Qilai Long, et al.. (2016). HSP90 Inhibitor Encapsulated Photo-Theranostic Nanoparticles for Synergistic Combination Cancer Therapy. Theranostics. 6(9). 1324–1335. 70 indexed citations

12.

Xiao, Wenwu, Tianhong Li, Diana Lac, et al.. (2016). Discovery and characterization of a high-affinity and high-specificity peptide ligand LXY30 for in vivo targeting of α3 integrin-expressing human tumors. EJNMMI Research. 6(1). 18–18. 27 indexed citations

13.

Amir, Sumaira, et al.. (2013). Abstract 3056: miR-125b suppresses p14ARF and modulates p53-dependent and p53-independent apoptosis in prostate cancer cells.. Cancer Research. 73(8_Supplement). 3056–3056. 4 indexed citations

14.

Chen, Siyu, Wei Tian, Ai‐Hong Ma, et al.. (2012). Antitumor effect of Chinese herb oridonin on human non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 30(15_suppl). e13526–e13526.

15.

Shi, Xu‐Bao, Lingru Xue, Ai‐Hong Ma, et al.. (2010). miR‐125b promotes growth of prostate cancer xenograft tumor through targeting pro‐apoptotic genes. The Prostate. 71(5). 538–549. 165 indexed citations

16.

Shi, Xu‐Bao, Ai‐Hong Ma, Clifford G. Tepper, et al.. (2004). Molecular alterations associated with LNCaP cell progression to androgen independence. The Prostate. 60(3). 257–271. 63 indexed citations

17.

Xia, Liang, Dan R. Robinson, Ai‐Hong Ma, et al.. (2002). Identification of Human Male Germ Cell-associated Kinase, a Kinase Transcriptionally Activated by Androgen in Prostate Cancer Cells. Journal of Biological Chemistry. 277(38). 35422–35433. 33 indexed citations

18.

Ma, Ai‐Hong, Liang Xia, Susan J. Littman, et al.. (2000). Somatic mutation of hPMS2 as a possible cause of sporadic human colon cancer with microsatellite instability. Oncogene. 19(18). 2249–2256. 23 indexed citations

19.

Eshleman, James R., et al.. (2000). Cytotoxicity and Mutagenicity of Frameshift-Inducing Agent ICR191 in Mismatch Repair-Deficient Colon Cancer Cells. JNCI Journal of the National Cancer Institute. 92(6). 480–485. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact